Literature DB >> 27268734

Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite.

David G Anderson1, Virginia R Florang1, Josephine H Schamp1, Garry R Buettner2, Jonathan A Doorn1.   

Abstract

3,4-Dihydroxyphenylacetaldehyde (DOPAL) is an endogenously produced toxic aldehyde. It is a bifunctional electrophile implicated in the loss of dopaminergic cells concomitant with Parkinson's disease and neurodegeneration. DOPAL is known to react with proteins and amino acids such as N-acetyl lysine (NAL); oxidation of the catechol moiety to the quinone of DOPAL increases this reactivity. Here, we demonstrate the ability of the antioxidants N-acetylcysteine, glutathione, and ascorbic acid to mitigate the reactivity of DOPAL with proteins and amino acids in a dose-dependent fashion. Conversely, Trolox did not lessen the observed reactivity with proteins. Interestingly, use of tricine, a buffer and reducing agent, in these systems also decreased the reactivity of DOPAL with amines, yielding tricine-derived free radical species. Modification of amines with aldehydes typically involves Schiff base chemistry; however, the observance of free radicals suggests that an oxidative step is involved in the reaction of DOPAL with lysine. Furthermore, while Schiff base formation is usually optimal at pH 5, the reaction rate of DOPAL with NAL is negligible at pH 5 and is enhanced under basic conditions (e.g., pH 9). Conditions of high pH are also favorable for catechol auto-oxidation, known to occur for DOPAL. The antioxidant-mediated protection demonstrated here suggests that oxidative stress may impart cellular vulnerability to protein modification by DOPAL. Therefore, depleted antioxidants and increased levels of lipid peroxidation products, known to prevent the detoxifying metabolism of DOPAL, may present a survival challenge to dopaminergic cells targeted in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27268734      PMCID: PMC5248556          DOI: 10.1021/acs.chemrestox.5b00528

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  46 in total

1.  Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine.

Authors:  William J Burke; Vijaya B Kumar; Neeraj Pandey; W Michael Panneton; Qi Gan; Mark W Franko; Mark O'Dell; Shu Wen Li; Yi Pan; Hyung D Chung; James E Galvin
Journal:  Acta Neuropathol       Date:  2007-10-27       Impact factor: 17.088

2.  Reactions of biogenic aldehydes with hemoglobin.

Authors:  A Helander; O Tottmar
Journal:  Alcohol       Date:  1989 Jan-Feb       Impact factor: 2.405

3.  Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde.

Authors:  I Lamensdorf; G Eisenhofer; J Harvey-White; Y Hayakawa; K Kirk; I J Kopin
Journal:  J Neurosci Res       Date:  2000-05-15       Impact factor: 4.164

4.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections.

Authors:  T G Hastings; D A Lewis; M J Zigmond
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

Review 5.  Thermodynamic and kinetic considerations for the reaction of semiquinone radicals to form superoxide and hydrogen peroxide.

Authors:  Yang Song; Garry R Buettner
Journal:  Free Radic Biol Med       Date:  2010-05-21       Impact factor: 7.376

6.  The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid.

Authors:  O I Aruoma; B Halliwell; B M Hoey; J Butler
Journal:  Free Radic Biol Med       Date:  1989       Impact factor: 7.376

7.  Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.

Authors:  Jennifer N Rees; Virginia R Florang; Laurie L Eckert; Jonathan A Doorn
Journal:  Chem Res Toxicol       Date:  2009-07       Impact factor: 3.739

Review 8.  Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases.

Authors:  William J Burke; Shu Wen Li; Hyung D Chung; David A Ruggiero; Bruce S Kristal; Eugene M Johnson; Patricia Lampe; Vijaya B Kumar; Mark Franko; Evelyn A Williams; Daniel S Zahm
Journal:  Neurotoxicology       Date:  2004-01       Impact factor: 4.294

Review 9.  Dementia with Lewy bodies.

Authors:  David Weisman; Ian McKeith
Journal:  Semin Neurol       Date:  2007-02       Impact factor: 3.420

10.  MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology.

Authors:  Jyothi K Mallajosyula; Deepinder Kaur; Shankar J Chinta; Subramanian Rajagopalan; Anand Rane; David G Nicholls; Donato A Di Monte; Heather Macarthur; Julie K Andersen
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

View more
  13 in total

1.  3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine.

Authors:  Yunden Jinsmaa; Yehonatan Sharabi; Patti Sullivan; Risa Isonaka; David S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2018-04-26       Impact factor: 4.030

2.  Biochemical characterization of the catecholaldehyde reactivity of L-carnosine and its therapeutic potential in human myocardium.

Authors:  Margaret-Ann M Nelson; Zachariah J Builta; T Blake Monroe; Jonathan A Doorn; Ethan J Anderson
Journal:  Amino Acids       Date:  2018-09-06       Impact factor: 3.520

Review 3.  Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky.

Authors:  David S Goldstein; Irwin J Kopin
Journal:  Cell Mol Neurobiol       Date:  2017-05-09       Impact factor: 5.046

4.  3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing α-Synuclein.

Authors:  Yunden Jinsmaa; Risa Isonaka; Yehonatan Sharabi; David S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2019-11-19       Impact factor: 4.030

Review 5.  The catecholaldehyde hypothesis: where MAO fits in.

Authors:  David S Goldstein
Journal:  J Neural Transm (Vienna)       Date:  2019-12-05       Impact factor: 3.575

6.  Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.

Authors:  Jonathan W Werner-Allen; Sarah Monti; Jenna F DuMond; Rodney L Levine; Ad Bax
Journal:  Biochemistry       Date:  2018-02-15       Impact factor: 3.162

Review 7.  Impaired dopamine metabolism in Parkinson's disease pathogenesis.

Authors:  Anna Masato; Nicoletta Plotegher; Daniela Boassa; Luigi Bubacco
Journal:  Mol Neurodegener       Date:  2019-08-20       Impact factor: 14.195

Review 8.  The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Authors:  David S Goldstein
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

9.  Stable expression of the human dopamine transporter in N27 cells as an in vitro model for dopamine cell trafficking and metabolism.

Authors:  B S Cagle; M L Sturgeon; J B O'Brien; J C Wilkinson; R A Cornell; D L Roman; J A Doorn
Journal:  Toxicol In Vitro       Date:  2021-07-05       Impact factor: 3.685

10.  In vitro inhibition of glutathione-S-transferase by dopamine and its metabolites, 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid.

Authors:  Rachel A Crawford; Kate R Bowman; Brianna S Cagle; Jonathan A Doorn
Journal:  Neurotoxicology       Date:  2021-07-24       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.